Thus, SGLT-1 may reduce NAFLD risk via improved glycaemic control, increased residual gastrointestinal (GI) tract glucose contributing towards favorable neuroendocrine hormone levels, or reduced post-prandial glucose load.10-12 Clinically, the use of the dual SGLT-1/2 inhibitor licogliflozin for 12 weeks reduced serum alanine transaminase (ALT) concentration in participants with NASH, but this randomized trial did not include participants across the NAFLD-disease spectrum.13 This evidence concerns the gene SLC5A1 and metabolic dysfunction-associated steatotic liver disease.